- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Anne L. Schwartz on Medicaid's Role in Addressing the Opioid Epidemic and Social Determinants of Health
Medicaid programs have been working to address to opioid epidemic in a number of ways and is starting to get involved in addressing social determinants of health, explained Anne L. Schwartz, PhD, executive director of the Medicaid and CHIP Payment and Access Commission.
Medicaid programs have been working to address to opioid epidemic in a number of ways and is starting to get involved in addressing social determinants of health, explained Anne L. Schwartz, PhD, executive director of the Medicaid and CHIP Payment and Access Commission.
Transcript
What has Medicaid’s role been in combating the opioid epidemic?
Medicaid programs have been working to address the opioid epidemic in a number of different ways. The first is obviously providing coverage for people who weren’t previously covered, and covering the treatment services associated with their substance use disorder. Medicaid programs have also been working with other state agencies, for example, pharmacy boards, to have better monitoring of prescribing practices and limits on the availability of prescription opioids.
What is the importance of addressing social determinants of health?
So, this is an area that I think is still really evolving. The research literature is pretty strong about the impact of different factors, such as education, poverty, living close to environmental hazards and the impact on health. The thing that’s tricky in the Medicaid program is that it is a program that provides medical assistance. And I think what you’re seeing now, states, health plans, advocates and others trying to sort it out what is basically an insurance vehicle to try and address some of these factors that affect health that are not normally a part of a health insurance package.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
